# A Dose Escalation and Dose Expansion Study of NOX66 in the Treatment of COVID-19

> **NCT04555213** · PHASE1 · COMPLETED · sponsor: **Noxopharm Limited** · enrollment: 41 (actual)

## Conditions studied

- Covid19

## Interventions

- **DRUG:** NOX66

## Key facts

- **NCT ID:** NCT04555213
- **Lead sponsor:** Noxopharm Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-09-30
- **Primary completion:** 2021-08-10
- **Final completion:** 2021-08-10
- **Target enrollment:** 41 (ACTUAL)
- **Last updated:** 2021-08-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04555213

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04555213, "A Dose Escalation and Dose Expansion Study of NOX66 in the Treatment of COVID-19". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04555213. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*